DaVita Inc. (NYSE:DVA) Shares Sold by Creekmur Asset Management LLC

Creekmur Asset Management LLC cut its stake in shares of DaVita Inc. (NYSE:DVA) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,720 shares of the company’s stock after selling 2,132 shares during the period. Creekmur Asset Management LLC’s holdings in DaVita were worth $1,005,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of DVA. Amundi grew its holdings in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after buying an additional 240,126 shares in the last quarter. FMR LLC boosted its position in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after acquiring an additional 154,061 shares during the period. Skandinaviska Enskilda Banken AB publ grew its stake in DaVita by 256.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after acquiring an additional 116,758 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company’s stock valued at $29,430,000 after buying an additional 84,375 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on DVA. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com downgraded DaVita from a “buy” rating to a “hold” rating in a report on Wednesday. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Finally, Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Trading Down 0.7 %

Shares of DVA stock opened at $151.82 on Wednesday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a fifty day moving average of $156.77 and a 200-day moving average of $157.44. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The stock has a market cap of $12.15 billion, a price-to-earnings ratio of 14.14, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.